Translation and Validation of MPCOSQ in Urdu Language
1 other identifier
observational
180
1 country
2
Brief Summary
To translate and validate modifies polycystic ovary syndrome quality of life (MPCOQ) questionnaire into Urdu. To evaluate the reliability, validity and of Urdu version of modified polycystic ovary syndrome quality of life questionnaire (MPCOQ).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2020
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2021
CompletedFirst Submitted
Initial submission to the registry
August 11, 2021
CompletedFirst Posted
Study publicly available on registry
August 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2021
CompletedApril 28, 2022
April 1, 2022
6 months
August 11, 2021
April 21, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Modified polycystic ovary syndrome quality of life questionnaire
The tool is to measure health related quality of life of females suffering from PCOS. it contains 30 items with 6 main areas related to hirsutism , acne, weight, infertility, emotional disturbance, menstrual difficulties to define different symptoms of PCOS. then quality of life will be measured of respective patients. The total is 210 with higher score indicating a better quality of life.
6 months
Eligibility Criteria
Patients diagnosed with PCOS
You may qualify if:
- Age 18 - 30
- Married
- Female patients diagnosed with PCOS, having 2 of the following Rotterdam diagnostic criteria:
- I. Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume \>10ml II. Clinical signs of hyperandrogenism (the hirsutism score based on the Ferriman-Gallwey score \>7 or obvious acne) III. Having an interval between menstrual periods \>35 days and/or amenorrhea as the absence of vaginal bleeding for at least 6 months, i.e. 199 days Patients who are willing to participate
You may not qualify if:
- Non-adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia
- Female undergoing Hormone Replacement Therapy
- Female with malignancies
- Any recent fractures, surgeries
- Patient with nephrological and neurological conditions
- Dementia or cognitive impairments
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Abeer Fatima
Islamabad, Punjab Province, 45000, Pakistan
Zohra Institute of Health Sciences
Rawalpindi, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sarah Ehsan
Riphah International University
- PRINCIPAL INVESTIGATOR
Abeer Fatima, MS(cppt)
Riphah International University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 11, 2021
First Posted
August 18, 2021
Study Start
November 20, 2020
Primary Completion
May 30, 2021
Study Completion
August 30, 2021
Last Updated
April 28, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will not share